Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.39 |
| ▸ | DRD1 | P21728 | 5/20 | 0.37 |
| ▸ | DRD5 | P21918 | 5/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | DRD3 | P35462 | 4/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3647466 | 0.86 | ESR1 (0.40) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL3652996 | 0.84 | ESR1 (0.40) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL3648881 | 0.84 | ESR1 (0.43) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL13875403 | 0.84 | ESR1 (0.43) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL3649486 | 0.84 | ESR1 (0.43) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL3657187 | 0.81 | ESR1 (0.38) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL3657954 | 0.81 | ESR2 (0.40) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL3653182 | 0.80 | ESR2 (0.45) | ESR1ESR2 | |
| SCHEMBL3653751 | 0.80 | OPRD1 (0.54) | ESR1ESR2DRD1DRD5DRD2 | |
| SCHEMBL3656789 | 0.77 | ESR2 (0.40) | ESR1ESR2DRD1DRD5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | claimed |
| EP-2048126-A1 | Benzocycloheptane derivatives as selectively active oestrogens | Bayer Schering Pharma AG (DE) | 2009-04-15 | — | — | EP | claimed |
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2048126-A1 | Benzocycloheptane derivatives as selectively active oestrogens | Bayer Schering Pharma AG (DE) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | CYP19A1, HSD17B11, CYP21A2 | ESR1 4/4885ESR2 23/4885DRD1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.